Literature DB >> 1001980

Histocompatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA-B27 (W27).

E G Mallas, P Mackintosh, P Asquith, W T Cooke.   

Abstract

Histocompatibility (HLA) antigen phenotypes have been studied in 100 patients with ulcerative colitis, 100 with Crohn's disease, and 283 normal controls. In addition the incidence of ankylosing spondylitis, sacroiliitis, and "enteropathic" peripheral arthropathy was determined in the patients with inflammatory bowel disease (IBD). There was no significant difference in antigen frequency between patients and controls. However, the incidence of HLA-B27 was increased in the patients complicated by ankylosing spondylitis and/or sacroiliitis in both ulcerative colitis and Crohn's disease. In contrast, none of the 29 IBD patients with "enteropathic" peripheral arthropathy had B27 antigen. Furthermore, ankylosing spondylitis was found more frequently in ulcerative colitis bearing HLA-B27 compared with non-B27 patients (P less than 0-01). The same was found in Crohn's disease, although this difference was not statistically significant. In addition, 12 of 14 ulcerative colitis patients and five out of six Crohn's patients with HLA-B27 had total colitis, compared with the frequency of total colitis in non-B27 patients (P less than 0-024 and less than 0-03 respectively). The data suggest that B27 histocompatibility antigen could be a pathogenetic discriminator between the arthropathies in IBD and may be of prognostic significance with respect to extension and severity of the disease.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1001980      PMCID: PMC1411211          DOI: 10.1136/gut.17.11.906

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  26 in total

1.  An association between ulcerative colitis, regional enteritis, and ankylosing spondylitis.

Authors:  E D ACHESON
Journal:  Q J Med       Date:  1960-10

2.  ARTHRITIC MANIFESTATIONS IN REGIONAL ENTERITIS.

Authors:  B M ANSELL; R A WIGLEY
Journal:  Ann Rheum Dis       Date:  1964-01       Impact factor: 19.103

3.  FAMILIAL OCCURRENCE OF REGIONAL ENTERITIS AND ULCERATIVE COLITIS.

Authors:  P SHERLOCK; B M BELL; H STEINBERG; T P ALMY
Journal:  Gastroenterology       Date:  1963-09       Impact factor: 22.682

4.  MICRODROPLET ASSAY OF HUMAN SERUM CYTOTOXINS.

Authors:  P I TERASAKI; J D MCCLELLAND
Journal:  Nature       Date:  1964-12-05       Impact factor: 49.962

5.  Diagnostic criteria for population studies.

Authors:  J H KELLGREN
Journal:  Bull Rheum Dis       Date:  1962-11

6.  HL-A 27 and arthropathies associated with ulcerative colitis and psoriasis.

Authors:  D A Brewerton; M Caffrey; A Nicholls; D Walters; D C James
Journal:  Lancet       Date:  1974-05-18       Impact factor: 79.321

7.  Histocompatibility antigens in patients with inflammatory-bowel disease.

Authors:  P Asquith; P Mackintosh; P L Stokes; G K Holmes; W T Cooke
Journal:  Lancet       Date:  1974-01-26       Impact factor: 79.321

8.  HL-A antigen 27 and reactive arthritis.

Authors:  K Aho; P Ahvonen; A Lassus; K Sievers; A Tilikainen
Journal:  Lancet       Date:  1973-07-21       Impact factor: 79.321

9.  HL-A 27 and Reiter's syndrome.

Authors:  J C Woodrow
Journal:  Lancet       Date:  1973-09-22       Impact factor: 79.321

10.  Ankylosing spondylitis and HL-A 27.

Authors:  D A Brewerton; F D Hart; A Nicholls; M Caffrey; D C James; R D Sturrock
Journal:  Lancet       Date:  1973-04-28       Impact factor: 79.321

View more
  20 in total

Review 1.  Clinical aspects and pathophysiology of inflammatory bowel disease.

Authors:  Barbara A Hendrickson; Ranjana Gokhale; Judy H Cho
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

2.  Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in a Japanese population.

Authors:  J Matsuzawa; K Sugimura; Y Matsuda; M Takazoe; K Ishizuka; T Mochizuki; S S Seki; O Yoneyama; H Bannnai; K Suzuki; T Honma; H Asakura
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

3.  Clinically silent infections in patients with oligoarthritis: results of a prospective study.

Authors:  C M Weyand; J J Goronzy
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

Review 4.  Extraintestinal manifestations and complications in IBD.

Authors:  Claudia Ott; Jürgen Schölmerich
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-09       Impact factor: 46.802

Review 5.  Extraintestinal manifestations and complications in inflammatory bowel diseases.

Authors:  Katja S Rothfuss; Eduard F Stange; Klaus R Herrlinger
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

6.  Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history.

Authors:  T R Orchard; B P Wordsworth; D P Jewell
Journal:  Gut       Date:  1998-03       Impact factor: 23.059

7.  HLA-A and -B antigens in inflammatory bowel disease.

Authors:  I Biemond; W R Burnham; J D'Amaro; M J Langman
Journal:  Gut       Date:  1986-08       Impact factor: 23.059

8.  An increased risk of Crohn's disease in individuals who inherit the HLA class II DRB3*0301 allele.

Authors:  D G Forcione; B Sands; K J Isselbacher; A Rustgi; D K Podolsky; S Pillai
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

9.  Ankylosing spondylitis and inflammatory bowel disease. III. Clinical characteristics and results of histocompatibility typing (HLA B27) in 50 patients with both ankylosing spondylitis and inflammatory bowel disease.

Authors:  B J Dekker-Saeys; S G Meuwissen; E M Van Den Berg-Loonen; W H De Haas; K A Meijers; G N Tytgat
Journal:  Ann Rheum Dis       Date:  1978-02       Impact factor: 19.103

10.  HLA B8 and granuloma formation in Crohn's disease.

Authors:  G Holdstock; B Macpherson; W L Beeken
Journal:  Gut       Date:  1982-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.